ÃâÒßѧÊÔÌâ
T wB}l Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
)iX~}7
1. Fas(CD95)/FasL
jwe *(k]z 2. common chain of cytokine receptor
g9pZ\$J& 3 . TCR/CD3 complex
$p8xEcQdU# 4. negaive selection of thymocytes
X #dmo/L8 5. artificial active immune
^#-l
q) 6. anti-idiotypic
;>hO+Wo 7. IgSF
R- wp9 ^ 8. Integrin
mUC)gA/ 9. chemokine
f5"k55 } 10. B7/CD28
%`r$g[<G ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©
B
IEO,W| 1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£
m@j?za9s 2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£
ssA`I<p # 3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£
atH*5X6d 5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½
^e5=hH-%
X05/uX{ 1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£
w"F
9l µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ
l4YbK np] Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
<nf@U>wlw 1. B7/CD28
g-k|>-h 2. Th1 subset
MY)O^I X$ 3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£©
C&f=
ywi0 4. antibody affinity maturation
dDMJ' 5. AP-1
tjS@meT 6. single chain variable fragment£¨ScFv£©
K3
m/(jdO 7. NK cell receptor
a!SiX 8. Zinkernagel-Doherty phenomenon
r<EY]f^`u 9. Ig fold
^CH=O|8j 10. CD40/CD40L
A@('pA85 ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£©
Pm?KI<TH~ 1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£
zI uJ-8T" 2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿
fbvL7*
( 3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿
W
i.&e Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩
>6-`}G+| 1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£
}v{LRRi 2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£
E&w
7GZNt 3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£
a-tmq]]E Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
Rv>-4@fMJ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£©
K5 z<3+ Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©
ATyEf5Id_ 1.Co-stimulators (or co-stimulating molecules)
w
JqMa9| 2.NK-kB
M3y NAN 3.Immunoglobulin superfamily
. Efk* 4.antigen-presenting cell (APC)
'Is kWgc 5.death domain
BlO<PMmhT& 6.CCR and CXCR
f~[7t:WD* 7.Lectin (or mitogen)
HiFUv>,u 8.Clusters of differentiation, CD)
!<";cw(q 9.B7 family
B6 ;|f'e! 10.Cytotoxic T lymphocyte, CTL)
!qg`/y9 11.IL-15 and IL-15 receptor (IL-15R)
z<;HQX, 12.MHC restriction
Fm 2AEs\ 13.Affinity-chromatography
#{6/ (X 14.Cyctosprin A, CsA
^
@5QP$. 15.Antibody-dependent cell-mediated cytotoxicity, ADCC)
B 3I`40# ¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©
O bS3
M 1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿
I236RIq 2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£
xC TML!H 3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£
am'7uy!ka~ Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©
8nJpp ÃâÒßѧרҵ£º
p2](_}PK 1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£
LRA8p<Rs Ïû»¯ÄÚ¿Æ£º
~!L}yw 2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£
;^*W+,4WB ѪҺ²¡Ñ§×¨Òµ£º
~0$&3a<n1 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿
u6agoK|^9 Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
+\9NDfYIA (רҵ»ù´¡: ÃâÒßѧ)
TJRCH>E[a Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)
Y3b *a".X 1. ADCC(antibody dependent cell-mediated cytotoxicity)
;_(4Q*Yx 2. »·æß¾úËØ(cyclosporin)
=,M5KDk` 3. KIR(killer cell inhibitory receptor)
R/YqyT\SM 4. HLDA(human leucocyte differentiation antigen)
iBaA9 5. Interleukin 18(IL-18)
+e``OeXog 6. ÕûºÏËØ(integrin)
S1_RjMbYM 7. Fas/FasL
w?[u pn:K 8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)
4r}51 N\ 9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)
g7H(PF? 10. Th1/Th2
M= (u]%\ 11. »ùÒòÒßÃç(DNAÒßÃç)
$UwCMPs X 12. chemokines and chemokine receptor
2^7`mES 13. ÃâÒßÄÍÊÜ
<hyKu
14. ¹²´Ì¼¤·Ö×Ó
a7opCmL 15. ËÀÍö½á¹¹Óò(death domain)
[
/r(__. ¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)
W>r+h
-kR 1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?
Pq$n5fZC! 2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óá£
"tK=+f`NM £¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î
At;LO9T3z £¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
i%?* @uj £¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå
$`8wJf9@w £¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹
sI2^Qp@O1 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£
H PVEnVn Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ)
[-
w%/D%@ ÎÊ´ðÌâ(ÿÌâ25·Ö)
*-
X[u: 1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£
UiNP3TJ'L 2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿
{!`6zBsP 3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£
]?4hyN 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£